Joseph Lacob
Known title: DirectorCIK: 0001215490
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating. Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.
Transaction History
| ALGN | ▲ Buy | Option Exercise | 1,745 | $0 | 5/20/2026 | View on chart |
| NPCE | ▲ Buy | Grant | 865 | $11K | 3/20/2026 | View on chart |
| NPCE | ▲ Buy | Grant | 678 | $11K | 12/19/2025 | View on chart |
| NPCE | ▲ Buy | Grant | 1,131 | $11K | 9/19/2025 | View on chart |
| NPCE | ▲ Buy | Grant | 1,080 | $11K | 6/21/2025 | View on chart |
| ALGN | ▲ Buy | Option Exercise | 1,148 | $0 | 5/21/2025 | View on chart |
| NPCE | ▲ Buy | Grant | 935 | $11K | 3/21/2025 | View on chart |
| NPCE | ▲ Buy | Grant | 975 | $11K | 12/21/2024 | View on chart |
| NPCE | ▲ Buy | Grant | 1,614 | $11K | 9/30/2024 | View on chart |
| NPCE | ▲ Buy | Grant | 1,488 | $11K | 6/28/2024 | View on chart |
| ALGN | ▲ Buy | Option Exercise | 1,029 | $0 | 5/17/2024 | View on chart |
| NPCE | ▲ Buy | Grant | 852 | $11K | 3/29/2024 | View on chart |
| ALGN | ▼ Sell | Open Market | 3,676 | $1.1M | 2/29/2024 | View on chart |
| ALGN | ▼ Sell | Open Market | 800 | $244K | 2/29/2024 | View on chart |
| ALGN | ▼ Sell | Open Market | 10,524 | $3.2M | 2/29/2024 | View on chart |
| ALGN | ▼ Sell | Open Market | 10,000 | $3.1M | 2/27/2024 | View on chart |
| NPCE | ▲ Buy | Grant | 1,091 | $11K | 12/29/2023 | View on chart |
| NPCE | ▲ Buy | Grant | 1,156 | $11K | 9/29/2023 | View on chart |
| NPCE | ▲ Buy | Grant | 2,505 | $11K | 6/30/2023 | View on chart |
| ALGN | ▲ Buy | Option Exercise | 1,114 | $0 | 5/17/2023 | View on chart |
| NPCE | ▲ Buy | Option Exercise | 192 | $5 | 10/18/2022 | View on chart |
| ALGN | ▲ Buy | Option Exercise | 524 | $0 | 5/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Align Technology Sets Q3 2026 Earnings Date for October 28
Align Technology has scheduled its third-quarter 2026 earnings release for October 28, 2026. This announcement comes as the stock trades near its 52-week low, prompting market discussions about whether the current valuation is reasonable after a significant decline. Analysts continue to watch the company's position in the dental equipment sector, with average price targets remaining above current levels.
Align Technology Sets Q3 2026 Earnings Date for October 28. Align Technology has scheduled its third-quarter 2026 earnings release for October 28, 2026. This announcement comes as the stock trades near its 52-week low, prompting market discussions about whether the current valuation is reasonable after a significant decline. Analysts continue to watch the company's position in the dental equipment sector, with average price targets remaining above current levels.